The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.

A microbial oil comprising: a specific amount of at least one polyunsaturated fatty acid having at least 20 carbon atoms in fatty acid alkyl ester form and/or in free fatty acid form; and specific amount of thermally-produced fatty acid having from 16 to 22 carbon atoms in a fatty acid alkyl ester form and/or a free fatty acid form. A production method thereof comprising: providing a starting oil containing at least one polyunsaturated fatty acid having at least 20 carbon atoms in an alkyl ester form and/or a free fatty acid form obtained from microbial biomass; performing a rectification of the starting oil under specific conditions; and obtaining the aforementioned microbial oil. A concentrated microbial oil obtained using the production method described above, and a production method thereof. An agent for treating or preventing an inflammatory disease comprising the microbial oil or the concentrated microbial oil.

A microbial oil comprising: a specific amount of at least one polyunsaturated fatty acid having at least 20 carbon atoms in fatty acid alkyl ester form and/or in free fatty acid form; and specific amount of thermally-produced fatty acid having from 16 to 22 carbon atoms in a fatty acid alkyl ester form and/or a free fatty acid form. A production method thereof comprising: providing a starting oil containing at least one polyunsaturated fatty acid having at least 20 carbon atoms in an alkyl ester form and/or a free fatty acid form obtained from microbial biomass; performing a rectification of the starting oil under specific conditions; and obtaining the aforementioned microbial oil. A concentrated microbial oil obtained using the production method described above, and a production method thereof. An agent for treating or preventing an inflammatory disease comprising the microbial oil or the concentrated microbial oil.

A preparation containing the mycoparasitic microorganism Pythium oligandrum for the treatment of dermatophytoses and yeast infections on the skin and mucous membranes obtained from a dry mixture containing 0.1 to 99.9% weight mycoparasitic microorganism Pythium oligandrum and 0.1 to 99.9% auxiliary substances, containing at least one component from a group comprising adsorbent, buffer, moisturizer, deodorant and aroma. This preparation contains 1 to 10×106, with preference of 10 to 50, viable cells of the Pythium oligandrum microorganism per 1 ml of aqueous suspension at the site of applying the preparation, whereby the viable cells of the Pythium oligandrum microorganism comprise dormant oospores, encysted zoospores and viable coenocytic mycelium. Different application methods of using the preparation are claimed. Exemplary embodiments show the viability of cells using genetic tests and practical tests conducted under the supervision of dermatologists, stomatologists and veterinarians.

A preparation containing the mycoparasitic microorganism Pythium oligandrum for the treatment of dermatophytoses and yeast infections on the skin and mucous membranes obtained from a dry mixture containing 0.1 to 99.9% weight mycoparasitic microorganism Pythium oligandrum and 0.1 to 99.9% auxiliary substances, containing at least one component from a group comprising adsorbent, buffer, moisturizer, deodorant and aroma. This preparation contains 1 to 10×106, with preference of 10 to 50, viable cells of the Pythium oligandrum microorganism per 1 ml of aqueous suspension at the site of applying the preparation, whereby the viable cells of the Pythium oligandrum microorganism comprise dormant oospores, encysted zoospores and viable coenocytic mycelium. Different application methods of using the preparation are claimed. Exemplary embodiments show the viability of cells using genetic tests and practical tests conducted under the supervision of dermatologists, stomatologists and veterinarians.

An endophytic fungus from gingko, that is, Fusarium proliferatum DZHQ1 having antitumor activity and antibacterial activity, is isolated from the ginkgo bark. The species of the strain is determined by the combination of colonial morphology and 18 sRNA sequencing, and then the anti-cervical cancer activity of a crude extract of the strain is detected by MTT. Finally, a secondary metabolite of the strain with an inhibition rate of more than 50% is isolated by semi-preparative HPLC, which promotes the further screening of individual compounds with anti-tumor activity. Moreover, the metabolite of the endophytic fungus from gingko shows a more pronounced inhibition in the detection of activity against E. coli and/or S. aureus, and has potential use in the preparation of new antibacterial products.

An endophytic fungus from gingko, that is, Fusarium proliferatum DZHQ1 having antitumor activity and antibacterial activity, is isolated from the ginkgo bark. The species of the strain is determined by the combination of colonial morphology and 18 sRNA sequencing, and then the anti-cervical cancer activity of a crude extract of the strain is detected by MTT. Finally, a secondary metabolite of the strain with an inhibition rate of more than 50% is isolated by semi-preparative HPLC, which promotes the further screening of individual compounds with anti-tumor activity. Moreover, the metabolite of the endophytic fungus from gingko shows a more pronounced inhibition in the detection of activity against E. coli and/or S. aureus, and has potential use in the preparation of new antibacterial products.

The subject invention provides microbe-based compositions comprising cultivated microorganisms and/or growth by-products thereof, as well as methods and systems for producing and using these compositions. More specifically, the subject invention provides microbe-based compositions comprising biologically pure yeast selected from the Pichia clade, and/or growth by-products thereof, such as biosurfactants, enzymes and solvents. Methods of using these compositions to enhance production in agriculture, horticulture, livestock rearing and aquaculture industries are also provided.

The subject invention provides microbe-based compositions comprising cultivated microorganisms and/or growth by-products thereof, as well as methods and systems for producing and using these compositions. More specifically, the subject invention provides microbe-based compositions comprising biologically pure yeast selected from the Pichia clade, and/or growth by-products thereof, such as biosurfactants, enzymes and solvents. Methods of using these compositions to enhance production in agriculture, horticulture, livestock rearing and aquaculture industries are also provided.

This disclosure provides for compositions (e.g., pharmaceutical compositions, dietary supplements, medical foods and food stuff), comprising combinations of live microbe populations for the treatment and/or prevention of immune system disorders and conditions related to inflammation, including both pathogen assisted conditions and conditions that are independent of pathogens. Included with the present disclosure are methods for use of the compositions, and methods for selecting microbial entities to formulate the compositions of the disclosure.